Sanofi's $2.2B Acquisition of Inhibrx Strengthens Drug Pipeline
Sanofi is acquiring California-based biotech company Inhibrx for up to $2.2 billion to bolster its pipeline of inflammation-targeting drugs, with a focus on Inhibrx’s experimental therapy for AATD, a disease affecting the lungs and liver. Inhibrx's other drug candidates, including cancer-targeting immunotherapies, will be part of a new company led by Inhibrx's founder and CEO.